Actinium Pharmaceuticals’ (ATNM) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Actinium Pharmaceuticals (NYSE:ATNM) in a report issued on Tuesday,Benzinga reports. They currently have a $4.00 price objective on the stock.

Actinium Pharmaceuticals Stock Down 7.5 %

Shares of Actinium Pharmaceuticals stock opened at $1.49 on Tuesday. Actinium Pharmaceuticals has a 12-month low of $1.03 and a 12-month high of $10.24. The company has a market capitalization of $46.48 million, a price-to-earnings ratio of -1.07 and a beta of 0.10. The firm’s 50-day moving average price is $1.26 and its two-hundred day moving average price is $1.44.

Institutional Trading of Actinium Pharmaceuticals

Large investors have recently bought and sold shares of the business. Wellington Management Group LLP acquired a new position in Actinium Pharmaceuticals during the third quarter worth about $112,000. XTX Topco Ltd bought a new stake in shares of Actinium Pharmaceuticals during the 3rd quarter valued at approximately $268,000. Barclays PLC increased its position in Actinium Pharmaceuticals by 323.0% during the 3rd quarter. Barclays PLC now owns 42,935 shares of the company’s stock worth $81,000 after purchasing an additional 32,784 shares in the last quarter. Geode Capital Management LLC lifted its stake in Actinium Pharmaceuticals by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock valued at $1,290,000 after purchasing an additional 19,843 shares during the last quarter. Finally, Vontobel Holding Ltd. acquired a new stake in Actinium Pharmaceuticals in the fourth quarter valued at approximately $32,000. 27.50% of the stock is owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).